# Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

> **NCT05132023** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Empagliflozin & Metformin (Test)
- **DRUG:** Empagliflozin & Metformin (Reference)

## Key facts

- **NCT ID:** NCT05132023
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2019-04-02
- **Final completion:** 2019-05-15
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132023, "Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05132023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*